Impel NeuroPharma to Present Data From INP104 Clinical Program at the 61st Annual Scientific Meeting of the American Headache Society
SEATTLE, July 10, 2019 /PRNewswire/ --Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announcedthat it will present four scientific abstracts at the 61st Annual Scientific Meeting of the American Headache Society (AHS) held July 11-14 in Philadelphia, PA.
"We continue to be encouraged by the safety, tolerability and comparative bioavailability data emerging from our INP104 clinical program in acute migraine. The data we are presenting at AHS suggest that elevations in systolic and diastolic blood pressure associated with dihydroergotamine mesylate (DHE) therapy are linked to the peak drug concentration achieved during intravenous administration, which INP104's upper nasal delivery route avoids," said Jon Congleton, President and Chief Executive Officer of Impel. "Moreover, because DHE has historically demonstrated efficacy independent of where a person is in a migraine cycle, INP104 has the potential to be a differentiated acute treatment for this debilitating disease."
The meeting abstracts are available online and can be accessed on the AHS meeting website at https://americanheadachesociety.org. All posters will be on display from Thursday, July 11 at 4:30 pm through Saturday, July 13 at 5:00 pm.
The following posters will have a Q&A session on Friday, July 12, 1:15 pm – 2:15 pm:
The following poster will have a Q&A session on Saturday, July 13, 1:00 pm – 2:15 pm:
These data that will be presented at the meeting support the ongoing "STOP-301 Trial" (Safety and Tolerability of POD-DHE), a Phase 3, open-label safety and tolerability study evaluating long-term, intermittent use of INP104 for the treatment of acute migraine.
About Acute Migraine
About Impel NeuroPharma
Impel's product candidates are delivered via its proprietary Precision Olfactory Delivery, or POD®, technology which targets the richly vascularized upper nasal cavity with the goal of achieving enhanced bioavailability of therapeutic molecules.
IMPEL, POD and the IMPEL Logo are trademarks of Impel NeuroPharma, Inc. To learn more about Impel NeuroPharma, please visit our website at http://impelnp.com.
About Precision Olfactory Delivery or POD® Devices
View original content to download multimedia:http://www.prnewswire.com/news-releases/impel-neuropharma-to-present-data-from-inp104-clinical-program-at-the-61st-annual-scientific-meeting-of-the-american-headache-society-300882919.html
SOURCE Impel NeuroPharma